Quarterly report · Q2
4539.TEDINET S100PJDF
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥16.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥32.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥15.6bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥167m | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥206m | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥752m | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.0bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥258m | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.2bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥258m | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥896m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥700m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥228m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥896m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥228m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥50.7bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥49.5bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥48.5bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥31.7bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥31.0bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥19.0bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥18.5bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥18.2bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥13.2bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥11.6bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥13.2bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.6bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.9bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.5bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥351m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.5bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥148m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥35m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥576m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥793m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥340m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥248.43 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥67.51 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥194.33 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥63.56 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥67.24 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 37.4% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.4% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.5% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥439m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥439m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | −¥16m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥6m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥6m |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥15.8bn |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥15.8bn |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥6m |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥183m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥16.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥16.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥6m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥167m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-09-30 | ¥480m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-09-30 | ¥460m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥20m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-09-30 | ¥11m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥30m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥30m |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥15.1bn |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥15.1bn |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥10m |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥194m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥15.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥15.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥30m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥206m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 547
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 15575000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 15575000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00957-000MedicineReportableSegmentsMember | 10000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 20000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 30000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -30000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00957-000MedicineReportableSegmentsMember | 15126000000 | JPY |
| Net sales | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 480000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 15606000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -30000000 | JPY |
| Net sales | Prior1YTDDuration | 15575000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00957-000MedicineReportableSegmentsMember | 194000000 | JPY |
| Operating income | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 11000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 206000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Operating income | Prior1YTDDuration | 206000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00957-000MedicineReportableSegmentsMember | 15798000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 439000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 16237000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 16237000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00957-000MedicineReportableSegmentsMember | 6000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 0 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 6000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -6000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00957-000MedicineReportableSegmentsMember | 15804000000 | JPY |
| Net sales | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 439000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 16244000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -6000000 | JPY |
| Net sales | CurrentYTDDuration | 16237000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00957-000MedicineReportableSegmentsMember | 183000000 | JPY |
| Operating income | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -16000000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 167000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Operating income | CurrentYTDDuration | 167000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2022-11-11 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第91期第２四半期(自 2022年７月１日 至 2022年９月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)日本ケミファ株式会社 | |
| Company name in english cover page | FilingDateInstant | NIPPON CHEMIPHAR CO., LTD. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 山 口 一 城 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都千代田区岩本町二丁目２番３号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京(03)3863－1211大代表 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)執行役員管理部長 中 島 慎 司 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都千代田区岩本町二丁目２番３号 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |